PMID- 21154235
OWN - NLM
STAT- MEDLINE
DCOM- 20110322
LR  - 20170213
IS  - 1699-5848 (Electronic)
IS  - 0213-3911 (Linking)
VI  - 26
IP  - 2
DP  - 2011 Feb
TI  - FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous 
      large B cell lymphoma, leg-type.
PG  - 213-21
LID - 10.14670/HH-26.213 [doi]
AB  - FOXP1 protein is expressed in normal activated B cells and overexpressed in a 
      subset of diffuse large B-cell lymphomas, including primary cutaneous large 
      B-cell lymphomas (PCLBCL), leg type. High expression of FOXP1 has been associated 
      to an unfavourable prognosis with independent survival significance. However, 
      little is known regarding the mechanisms underlying the overexpression of FOXP1 
      in PCLBCL, leg type. Our aims were to analyze FOXP1 cytogenetic status and 
      protein expression in a series of PCLBCL, leg type. Finally, we compared the 
      observed results with those obtained in a group of patients with primary 
      cutaneous follicle centre lymphoma (PCFCL). Fifteen patients with PCLBCL, leg 
      type and nine patients with primary cutaneous follicle centre lymphoma (PCFCL) 
      were included in the study. For each biopsy specimen, FOXP1 translocation and 
      copy number changes were evaluated by fluorescence in situ hybridization (FISH) 
      and protein expression by immunohistochemistry (IHC). Immunohistochemistry showed 
      FOXP1 staining in 13 PCLBCL, leg type, whereas all PCFCL were negative. FISH 
      analysis disclosed no translocations involving FOXP1 gene in any of the cases. 
      However, FOXP1 gene gains (3 to 4 copies) were observed in 82% of samples of 
      PCLBCL, leg type and in 37% of PCFCL. FOXP1 expression was independent from FOXP1 
      translocation. Our results confirm that overexpression of FOXP1 is present in a 
      considerable proportion of PCLBCL, leg type and might indicate an unfavourable 
      prognosis. Mechanisms not related to translocation seem to be responsible for 
      this overexpression.
FAU - Espinet, Blanca
AU  - Espinet B
AD  - Servei de Patologia (Laboratori de Citogenetica i Biologia Molecular), 
      IMIM-Hospital del Mar, GRETNHE, IMIM. Barcelona, Spain. 
      bespinet@parcdesalutmar.cat
FAU - Garcia-Herrera, Adriana
AU  - Garcia-Herrera A
FAU - Gallardo, Fernando
AU  - Gallardo F
FAU - Baro, Cristina
AU  - Baro C
FAU - Salgado, Rocio
AU  - Salgado R
FAU - Servitje, Octavio
AU  - Servitje O
FAU - Estrach, Teresa
AU  - Estrach T
FAU - Colomo, Lluis
AU  - Colomo L
FAU - Romagosa, Vicenc
AU  - Romagosa V
FAU - Barranco, Carlos
AU  - Barranco C
FAU - Serrano, Sergi
AU  - Serrano S
FAU - Campo, Elias
AU  - Campo E
FAU - Pujol, Ramon Ma
AU  - Pujol RM
FAU - Sole, Francesc
AU  - Sole F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Spain
TA  - Histol Histopathol
JT  - Histology and histopathology
JID - 8609357
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (FOXP1 protein, human)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Repressor Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/metabolism
MH  - Chromosome Aberrations
MH  - Female
MH  - Forkhead Transcription Factors/*genetics/metabolism
MH  - Gene Dosage
MH  - Gene Duplication
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Leg/pathology
MH  - Lymphoma, Follicular/genetics/metabolism
MH  - Lymphoma, Large B-Cell, Diffuse/*genetics/metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Repressor Proteins/*genetics/metabolism
MH  - Retrospective Studies
MH  - Skin Neoplasms/*genetics/metabolism/pathology
EDAT- 2010/12/15 06:00
MHDA- 2011/03/23 06:00
CRDT- 2010/12/15 06:00
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2011/03/23 06:00 [medline]
AID - 10.14670/HH-26.213 [doi]
PST - ppublish
SO  - Histol Histopathol. 2011 Feb;26(2):213-21. doi: 10.14670/HH-26.213.